Showing results (241-250 of 300) with videos related to
Sort By:
Pageof 30
Journal of the International AIDS Society|March 22, 2021
Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United StatesDavid C Boettiger, Anthony T Newall, Andrew Phillips, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR CohortCaroline Besson, Remi Lancar, Sophie Prevot, et al.Diabetes Research and Clinical Practice|December 24, 2019
Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA studyValentine Suteau, Pierre-Jean Saulnier, Matthieu Wargny, et al.Trials|November 9, 2022
Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trialThomas Maitre, Maryline Bonnet, Alexandra Calmy, et al.Annals of Internal Medicine|October 18, 2016
Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort StudyQing Wang, Andrea De Luca, Colette Smith, et al.ESC Heart Failure|February 11, 2021
Type 2 diabetes and heart failure: insights from the global DISCOVER studySuzanne V Arnold, Kamlesh Khunti, Fabrice Bonnet, et al.International Journal of Antimicrobial Agents|July 13, 2026
Outcomes for persons with triple-class resistant HIV and a history of virologic failureSuzanne M Ingle, Fabrice Bonnet, Linda Wittkop, et al.Open Forum Infectious Diseases|December 14, 2019
Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced PatientsFlaminia Olearo, Huyen Nguyen, Fabrice Bonnet, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 10, 2024
Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical SettingsCelia Jonsson-Oldenbüttel, Jade Ghosn, Marc van der Valk, et al.Journal of Hypertension|September 1, 2007
Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS studyJoël Constans, Christine Germain, Philippe Gosse, et al.Pageof 30